1. Academic Validation
  2. Artificial Macrocycles as IL-17A/IL-17RA Antagonists

Artificial Macrocycles as IL-17A/IL-17RA Antagonists

  • Medchemcomm. 2018 Jan 1;9(1):22-26. doi: 10.1039/C7MD00464H.
Wenjia Wang 1 Matthew R Groves 1 Alexander Dömling 1
Affiliations

Affiliation

  • 1 Department of Drug Design, University of Groningen, A. Deusinglaan 1, Groningen, The Netherlands.
Abstract

Interleukin 17(A) is a pro-inflammatory cytokine involved in several auto-immune and inflammatory diseases. Current antagonists against IL17(A) or its receptor (IL17R) that show efficacy in clinical trials are monoclonal-antibodies (mAbs). However, recently designed artificial macrocyles are potent IL17-IL17R antagonists. Based on Co-crystal structures, a better understanding the biological activity and SAR of the macrocycles has been elucidated, demonstrating that macrocycles can compete with mAbs for difficult targets such as PPIs.

Figures
Products